Voyager Therapeutics (NASDAQ:VYGR – Free Report) had its price target trimmed by Canaccord Genuity Group from $14.00 to ...

Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics ...

NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ...

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.

Q4 2024 Earnings Call Transcript March 11, 2025 Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago.

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.

Canaccord lowered the firm’s price target on Voyager Therapeutics (VYGR) to $12 from $14 and keeps a Buy rating on the shares. The firm said ...

Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of ...

The gene therapy company posted revenue of $6.3 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $20.1 million. For the year, the company reported a ...

Good afternoon, and welcome to Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a ...